News

People with diffuse cutaneous scleroderma (dcSSc) being treated with lenabasum continue to show improvement after more than two years of the therapy, an update from a Phase 2 extension study shows. The research, “…

Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: The Rare Disease Film Festival strives to eventually host a film about every one of the nearly 7,000 rare…

Black patients with scleroderma experience faster disease progression, higher prevalence of diffuse skin involvement, and higher mortality than Asian or white patients, a study reports. In addition, Asian patients were found to have earlier disease onset, faster disease course, and more lung involvement and pulmonary hypertension…

Treatment with Ofev (nintedanib) slows the rate of lung function decline in people with autoimmune-related interstitial lung diseases (ILDs), including scleroderma, a new analysis shows. Those are the results of the global Phase 3 INBUILD study (NCT02999178), which evaluated the therapeutic benefits of Ofev in people with…

People with scleroderma who were younger and had thicker skin at the onset of their disease experience an increased risk of heart muscle (myocardial) inflammation, a new study suggests. The research, “Clinical and laboratory predictions of myocardial inflammation as detected by cardiac magnetic resonance imaging in patients with…

Treatment with Letairis (ambrisentan) failed to significantly reduce pulmonary blood pressure at rest and during exercise compared with a placebo in people with scleroderma and mild pulmonary hypertension (PH), a Phase 2 trial showed. However, the therapy improved cardiac function and blood flow in the lungs —…

Most people with scleroderma develop skin lesions within one year after the onset of Raynaud’s phenomenon (RP), a condition in which the fingers and toes feel numb, prickly, and frigid in response to cold temperatures or stress, a 10-year follow-up study reports.  The findings also showed a continuous…

Digital ulcers (DUs) aggravate hand disability, limit daily activities, and affect work productivity in people with scleroderma, a real-world study from Spain reports. Patients with DUs had more pain, a higher incidence of Raynaud’s phenomenon, and reported having…

Real-world clinical data support the use of Opsumit (macitentan) to treat people with pulmonary arterial hypertension (PAH) due to scleroderma (PAH-SSc). The findings revealed similar safety results and comparable therapeutic efficacy in people with PAH-SSc as seen in patients with idiopathic or hereditary…

A recently discovered variant of the IFNL3 gene increases the risk of pulmonary fibrosis (PF) in people with scleroderma, a study reveals. In contrast, no such link was found between this variant and worsened skin fibrosis in these patients. Findings also revealed markedly increased serum levels of…